TRBD2: A Potential Drug Target for Cancer (G28636)

Target Name: TRBD2

NCBI ID: G28636

TRBD2

Other Name(s): TCRBD2 | T cell receptor beta diversity 2

TRBD2: A Potential Drug Target for Cancer

TRBD2 (Tumor-associated RNA-protein Binding Domain 2) is a protein that is expressed in various tissues of the body, including the brain, spleen, heart, and lymph nodes. It is a member of the RNA-protein binding family, which includes proteins that interact with specific RNA molecules to regulate gene expression.

One of the unique features of TRBD2 is its ability to interact with specific RNA molecules that are expressed in cancer cells. This interaction allows TRBD2 to play a role in the regulation of cancer cell growth, proliferation, and survival.

TRBD2 has also been shown to interact with the protein p21 (T-cell antigen 4), which is a well-known tumor suppressor protein that is often expressed in cancer cells. The interaction between TRBD2 and p21 has been shown to promote the growth and survival of cancer cells, which suggests that TRBD2 may be a potential drug target or biomarker for cancer.

In addition to its interaction with p21, TRBD2 has also been shown to interact with several other proteins that are involved in the regulation of cell growth and differentiation. These interactions may help to further clarify the role of TRBD2 in the regulation of cancer cell growth and differentiation. survival.

Overall, TRBD2 is a protein that has significant potential as a drug target or biomarker for cancer. Further research is needed to fully understand its role in the regulation of cancer cell growth and survival.

Protein Name: T Cell Receptor Beta Diversity 2

The "TRBD2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRBD2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets